EICHORCondition: Plaque Psoriasis · Sponsor: Janssen Research & Development, LLC
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Alliance Dermatology and MOHS Center P C | Phoenix, Arizona, United States | — |
| California Dermatology & Clinical Research Institute | Encinitas, California, United States | — |
| T Joseph Raoof Md Inc | Encino, California, United States | — |
| UCSF Fresno | Fresno, California, United States | — |
| University of California Los Angeles - Division of Dermatology | Los Angeles, California, United States | — |
| Wallace Medical Group, Inc | Los Angeles, California, United States | — |
| Dermatologist Medical Group of North County, Inc. | Oceanside, California, United States | — |
| Miami Dermatology And Laser Institute | Miami, Florida, United States | — |
| Bioclinical Research Alliance Inc. | Miami, Florida, United States | — |
| Forcare Clinical Research Inc | Tampa, Florida, United States | — |
| Southeast Dermatology Specialists | Douglasville, Georgia, United States | — |
| Arlington Dermatology | Rolling Meadows, Illinois, United States | — |
+ 116 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06220604